Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Research context
Active Biotech AB (publ) appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Active Biotech AB (publ) is currently in a long term downtrend where the price is trading 15.2% below its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 36.8.
Active Biotech AB (publ)'s total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 27.0% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 56.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Active Biotech AB (publ) gets an overall score of 3/5.